Boston-based Beacon Biosignals designed its Dreem 3S headband with integrated machine-learning algorithms. The advanced wearable headband features six electrodes and an integrated accelerometer to measure head movement and body position. Itcaptures EEG data from the brain to monitor sleep architecture and aid in diagnosing disturbed sleep.
The system received FDA clearance in September 2023, then got clearance for updated algorithms earlier this month.
Beacon Biosignals says its easy-to-use device makes it simple for patients to participate in clinically validated EEG-based sleep monitoring. By using it at home, patients can unlock new insights into sleep physiology. Dreem 3S — the first dry-EEG medical device of its kind — allows for convenient data collection at home, according to the company. Patients use the device independently, with recordings lasting for 24 hours.
The company presented two scientific posters this week at the American Epilepsy Society (AES) Annual Meeting. They highlighted work around advancing the understanding of sleep disturbances in individuals with Lennox-Gastaut Syndrome (LGS) and their caregivers.
More about the new insights from Beacon Biosignals
In partnership with Longboard Pharmaceuticals, the company reported preliminary findings from the Dreem LGS Caregiver Study. It uses Dreem 3S to explore sleep disturbances in caregivers of children with LGS.
Results demonstrated that caregivers successfully utilized the at-home EEG device over multi-night recordings. THey captured high-quality data without requiring technologist intervention. The study found a significant increase in wake after sleep onset (WASO) in LGS caregivers of 37.79 minutes vs. 24.70 minutes in controls, as well as shortened sleep onset latency of 14.62 minutes vs. 23.43 minutes in controls. Beacon Biosignals said the insights provide an essential foundation for understanding the intersection of caregiver burden, stress, and sleep quality in this underserved population.
The second poster, developed in collaboration with UCB, focused on the HEADFIRST study. That study evaluates sleep architecture in children with LGS compared to neurotypical siblings. Using Dreem 3S, it identified marked disturbances in sleep patterns among LGS participants. Those included increased WASO and fewer sleep cycles. LGS participants also showed a significant reduction in REM sleep
New Insights into Sleep Architecture in LGS (56.77 minutes, vs. 104.34 minutes in controls), falling in line with the neurological underpinnings of the syndrome.
Beacon Biosignals said the results can help it assess how Dreem 3S overcomes challenges posted by traditional wired EEG systems.
“Our AES presentations this year demonstrate the transformative potential of Beacon’s technology in advancing neurodiagnostics,” said David Matthews, chief business officer of Beacon Biosignals. “By collaborating with industry leaders like UCB and Longboard, we are uncovering critical insights into epilepsy-related sleep disorders, supporting the development of novel therapies, and ultimately improving outcomes for patients and their families.”
